Laden…
High Risk: Respiratory depression risk from mu-opioid agonism and GABA-A potentiation
Synapedia classifies this as a high-risk interaction context. Warning signs should be taken seriously and medically assessed. This page can provide source-linked orientation, but it is not medical advice, a dosing guide or a claim that the combination can be made safe.
O-DSMT is the primary active mu-opioid metabolite of tramadol and suppresses respiratory drive through mu-opioid receptors in the brainstem. Benzodiazepines potentiate GABAergic inhibition through GABA-A receptors. Together, these complementary receptor systems can produce additive central respiratory depression. Unlike tramadol, O-DSMT does not have SERT or NET inhibition, so the main combination risk is opioid-benzodiazepine respiratory depression rather than serotonin syndrome. O-DSMT effects can be difficult to assess because of individual variation in CYP2D6 metabolism and direct use of O-DSMT as a substance. Naloxone can antagonize the O-DSMT-mediated opioid component.
Mechanism data is language-neutral pharmacological notation. It does not provide amounts, timing or instructions for combining substances.
Pair-specific warning signs have not yet been curated. Breathing problems, loss of consciousness, seizures, chest pain, high fever, collapse or severe confusion remain medical red flags.
If acute symptoms appear, seek emergency medical help. Do not wait when breathing, consciousness, seizures, chest pain or severe confusion are involved.
O-DSMT is the primary active mu-opioid metabolite of tramadol and suppresses respiratory drive through mu-opioid receptors in the brainstem. Benzodiazepines potentiate GABAergic inhibition through GABA-A receptors. Together, these complementary receptor systems can produce additive central respiratory depression. Unlike tramadol, O-DSMT does not have SERT or NET inhibition, so the main combination risk is opioid-benzodiazepine respiratory depression rather than serotonin syndrome. O-DSMT effects can be difficult to assess because of individual variation in CYP2D6 metabolism and direct use of O-DSMT as a substance. Naloxone can antagonize the O-DSMT-mediated opioid component.
O-DSMT ist der primäre aktive μ-Opioid-Metabolit von Tramadol und hemmt den Atemantrieb über μ-Opioidrezeptoren im Hirnstamm — Benzodiazepine potenzieren die GABAerge Hemmung über GABA-A-Rezeptoren = additive zentrale Atemdepression über komplementäre Rezeptorsysteme
Important red flags include breathing problems, loss of consciousness, seizures, chest pain, high fever, collapse or severe confusion. Acute symptoms require medical help and this page does not replace emergency care.
This entry includes class-based pharmacology and should not be read as an individual clinical assessment. The page links 3 sources.
This page is based on curated pharmacological data and/or community signals. It is intended for scientific education and harm reduction only. It does not replace professional medical advice. Not all interactions are covered — always consult a healthcare professional when in doubt. In emergencies, call your local emergency number.